THE ROLE OF CHEMOTHERAPY INCLUDING IFOSFAMIDE FOR OVARIAN-CARCINOMA

被引:0
|
作者
KARRER, K [1 ]
SALZER, H [1 ]
SEVELDA, P [1 ]
DITTRICH, C [1 ]
机构
[1] UNIV VIENNA,DEPT CHEMOTHERAPY,A-1090 VIENNA,AUSTRIA
关键词
D O I
10.1007/BF00685413
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
On the basis of the results of earlier studies, 30 departments of gynecology have been cooperating nationwide in Austria since 1980 to promote the use of adjuvant chemotherapy after surgery for cure of ovarian carcinoma in early stages and the role of lymph node dissection and of second-look operation. Results recorded in more than 160 patients treated with adjuvant chemotherapy after so-called radical surgery performed in disease stages I and II demonstrate that only highly differentiated tumours in stage Ia can be cured by surgery only with no further adjuvant treatment. This underlines the necessity for staging. More than 200 patients with TNM stages III and IV were randomized after debulking surgery to receive treatment with different kinds of drug combinations to compare the therapeutic efficacy of a sequential alternating drug regimen consisting of Adriamycin-cisplatin+vincristine-cyclophosphamide+high-dose methotrexate with that of the combination of Adriamycin-cyclophosphamide and that of Adriamycin-cisplatin. High-dosed ifosfamide was also used in pilot studies. © 1990 Springer-Verlag.
引用
收藏
页码:S30 / S32
页数:3
相关论文
共 50 条
  • [41] INTRAPERITONEAL CISPLATIN-BASED CHEMOTHERAPY FOR OVARIAN-CARCINOMA
    HOWELL, SB
    KIRMANI, S
    MCCLAY, EF
    KIM, S
    BRALY, P
    PLAXE, S
    SEMINARS IN ONCOLOGY, 1991, 18 (01) : 5 - 10
  • [42] CYTOLOGIC EXAMINATIONS OVER THE COURSE OF OVARIAN-CARCINOMA CHEMOTHERAPY
    YAKIMOVA, TP
    YAKOVTSOVA, II
    SAMSONOVA, LA
    SKRIPNIK, LD
    PAVLOVA, TD
    LABORATORNOE DELO, 1990, (07): : 42 - 44
  • [43] INTERVAL LAPAROSCOPY AS PREDICTOR OF RESPONSE TO CHEMOTHERAPY IN OVARIAN-CARCINOMA
    LELE, SB
    PIVER, MS
    OBSTETRICS AND GYNECOLOGY, 1986, 68 (03): : 345 - 347
  • [44] COMBINATION CHEMOTHERAPY AND IMMUNE CAPACITY IN ADVANCED OVARIAN-CARCINOMA
    TENBERGE, RJM
    SCHELLEKENS, PTA
    HAMERLYNCK, JVTH
    BRUNING, PF
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (01): : 91 - 98
  • [45] NEOADJUVANT CHEMOTHERAPY IN STAGE-X OVARIAN-CARCINOMA
    CHAMBERS, JT
    CHAMBERS, SK
    VOYNICK, IM
    SCHWARTZ, PE
    GYNECOLOGIC ONCOLOGY, 1990, 37 (03) : 327 - 331
  • [46] DOSE INTENSITY ANALYSIS OF CHEMOTHERAPY REGIMENS IN OVARIAN-CARCINOMA
    LEVIN, L
    HRYNIUK, WM
    JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (05) : 756 - 767
  • [47] COMBINED CHEMOTHERAPY SIDE-EFFECTS IN OVARIAN-CARCINOMA
    MOROZ, LV
    RYZHAKOV, VM
    MARENICH, AF
    SOVETSKAYA MEDITSINA, 1989, (12): : 97 - 100
  • [48] OVARIAN-CARCINOMA
    SPECHTER, HJ
    THERAPEUTISCHE UMSCHAU, 1979, 36 (06) : 518 - 523
  • [49] OVARIAN-CARCINOMA
    CARNEY, DN
    IRISH JOURNAL OF MEDICAL SCIENCE, 1989, 158 (01) : 1 - 3
  • [50] THE ROLE OF HEXAMETHYLMELAMINE IN ADVANCED OVARIAN-CARCINOMA TREATMENT
    WEISS, RB
    GYNECOLOGIC ONCOLOGY, 1981, 12 (02) : 141 - 149